Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Inc., Next Phase Study of Ifenprodil for COVID-19 Treatment, CEO Clip Video

Newsfile August 25, 2020

Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire August 25, 2020

Algernon Updates Market on Analyst Coverage by Mackie Research

GlobeNewswire August 24, 2020

Algernon Announces Research Analyst Coverage by Mackie Research with an $0.80/share Target Price

GlobeNewswire August 24, 2020

Algernon CEO Presents Corporate Update Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire August 17, 2020

First US Patient in Algernon’s COVID-19 Treatment Study Steps Forward

Stockhouse Editorial August 13, 2020

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire August 13, 2020

Ifenprodil: The Drug That Tamed the World's Most Lethal Flu has its Debut for COVID

Livemoney August 12, 2020

IIROC Trade Resumption - AGN

Canada NewsWire August 5, 2020

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire August 5, 2020

IIROC Trading Halt - AGN

Canada NewsWire August 5, 2020

Algernon Doses 1st Patient in Phase 2 Chronic Cough Trial

Stockhouse Editorial August 5, 2020

LD Micro Announces Preliminary List of Presenters for the LD 500

Accesswire August 5, 2020

Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil

GlobeNewswire August 5, 2020

First US Clinical Trial for Possible COVID-19 Treatment About to Start

Dave Jackson July 24, 2020

Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment

GlobeNewswire July 21, 2020

COVID-19: Algernon Announces First U.S. Clinical Trial Site in Florida

Featured Press Release July 16, 2020

Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire July 16, 2020

Algernon Screening Patients for Phase 2 Ifenprodil IPF & Chronic Cough Study in Australia

Stockhouse Editorial July 7, 2020

Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

GlobeNewswire July 7, 2020